Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 6, 2002, Pages 461-467

  Jacobson, P ^a   Green, K ^a   Birnbaum, A ^a   Remmel, R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cytochrome P450; Human microsomes; Metabolism; TEPA; Thiotepa

Indexed keywords

4 METHYLPYRAZOLE; ALKYLATING AGENT; COUMARIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DISULFIRAM; ENZYME ANTIBODY; FURAFYLLINE; ISOENZYME; KETOCONAZOLE; LIVER ENZYME; MONOCLONAL ANTIBODY; OMEPRAZOLE; PACLITAXEL; QUINIDINE; SULFAPHENAZOLE; TEPA; THIOTEPA; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; MALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; THIOTEPA; TRANSFECTION; TRIETHYLENEPHOSPHORAMIDE;

EID: 0036090053     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0453-3     Document Type: Article

References (44)

1. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide
2. High-dose thiotepa alone and in combination regimens with bone marrow support
3. High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas
4. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
5. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450
6. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
7. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes
8. Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells
9. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites
10. Interaction of N,N′,N″-triethylenethiophosphoramide and N,N′,N″-triethylenephosphoramide with cellular DNA
11. 32P-labelled triethylene-phosphoramide in relation to its anti-tumour activity
12. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa
13. Further characterization of the expression in liver and catalytic activity of CYP2B6
14. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone
15. Identification of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent
16. Human CYP2B6: Expression, inducibility and catalytic activities
17. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients
18. Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver
19. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors
20. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer
21. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
22. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence-dependency in high-dose chemotherapy regimens
23. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies
24. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
25. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer
26. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors
27. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4
28. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
29. Biotransformation of N,N′,N″-triethylenethiophosphoramide: Oxidative desulfuration to yield N,N′,N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase
30. N,N′,N″-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents
31. Phase I/pharmacokinetic reevaluation of thioTEPA
32. Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms
33. Dosing of thioTEPA for myeloablative therapy
34. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8
35. Use of in vitro human metabolism studies in drug development. An industrial perspective
36. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes, P450 and native human liver microsomes
37. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia
38. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease
39. Determination of N,N′,N″-triethylenethiophosphoramide and its active metabolite N,N′,N′-triethylenephosphoramide in plasma and urine using capillary gas chromatography
40. A search for new metabolites of N,N′,N″-triethylenethiophosphoramide
41. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate
42. Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (thioTEPA)
43. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin
44. High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies